CardioGenics (CGNH) 10-Q 22 Sep 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Jul. 31, 2014	Sep. 19, 2014
Document And Entity Information	'	'
Entity Registrant Name	'CardioGenics Holdings Inc.	'
Entity Central Index Key	'0001089029	'
Document Type	'10-Q	'
Document Period End Date	31-Jul-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--10-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock Shares Outstanding	'	42,119,729
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2014	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Jul. 31, 2014	Oct. 31, 2013
Current Assets	'	'
Cash and Cash Equivalents	$14,357	$263,103
Accounts Receivable	236	246
Deposits and Prepaid Expenses	47,173	49,267
Refundable Taxes Receivable	3,882	3,302
Government Grants and Investment Tax Credits Receivable	71,322	60,104
Current Assets, Total	136,970	376,022
Long-Term Assets	'	'
Property and Equipment, net	45,538	53,496
Patents, net	113,291	118,432
Long Term Asset, Total	158,829	171,928
Total Assets	295,799	547,950
Current Liabilities	'	'
Accounts Payable and Accrued Expenses	1,053,695	1,050,115
Funds Held in Trust for Redemption of Class B Common Shares	4	4
Due to Shareholder	22,957	'
Notes Payable, net of debt discount	41,206	11,983
Derivative Liability on Notes Payable	428,675	99,702
Total current liabilities	1,546,537	1,161,804
Long-Term Liabilities	'	'
Debentures Payable	477,883	303,190
Total Liabilities	2,024,420	1,464,994
Commitments and Contingencies	'	'
Deficiency	'	'
Preferred stock; par value $.0001 per share, 50,000,000 shares authorized, none issued	'	'
Common stock; par value $.00001 per share; 150,000,000 shares authorized, 36,862,476 and 34,726,668 common shares and 24,176,927 and 24,176,927 exchangeable shares issued and outstanding as at July 31, 2014 and October 31, 2013 respectively	587	565
Additional paid-in capital	44,593,531	44,514,000
Accumulated deficit	-46,271,639	-44,957,870
Accumulated other comprehensive loss	-51,100	-117,515
Total deficiency attributable to CardioGenics Holdings Inc.	-1,728,621	-560,820
Non-controlling interest	'	-356,224
Total deficiency	-1,728,621	-917,044
Total liabilities and deficiency	$295,799	$547,950

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Jul. 31, 2014	Oct. 31, 2013
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	'	'
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	150,000,000	150,000,000
Common Stock [Member]	'	'
Common stock, shares issued	36,862,476	34,726,668
Common stock, shares outstanding	36,862,476	34,726,668
Exchangeable Shares [Member]	'	'
Common stock, shares issued	24,176,927	24,176,927
Common stock, shares outstanding	24,176,927	24,176,927

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014	Jul. 31, 2013
Income Statement [Abstract]	'	'	'	'
Revenue	'	'	'	'
Operating Expenses	'	'	'	'
Depreciation and Amortization of Property and Equipment	2,740	3,374	8,168	10,341
Amortization of Patent Application Costs	1,724	1,660	5,140	5,089
General and Administrative	107,751	138,530	375,796	344,177
Research and Product Development, Net of Investment Tax Credits	85,241	90,060	275,916	288,546
Total operating expenses	197,456	233,624	665,020	648,153
Operating Loss	-197,456	-233,624	-665,020	-648,153
Other Expenses (Income)	'	'	'	'
Interest Expense and Bank Charges (Net)	142,256	95,897	379,836	132,613
Loss (Gain) on Change in Fair Value of Derivative Liability	246,430	3,531	247,249	-7,250
Loss (Gain) on Foreign Exchange Transactions	-20,515	-15,820	21,664	-11,897
Total other expenses income	368,171	83,608	648,749	113,466
Net Loss	-565,627	-317,232	-1,313,769	-761,619
Net Loss attributable to non-controlling interest	'	-1,804	'	-4,525
Net Loss attributable to CardioGenics Holdings Inc.	($565,627)	($315,428)	($1,313,769)	($757,094)
Basic and Fully Diluted Net Loss per Common Share attributable to CardioGenics Holdings Inc. Shareholders	($0.01)	$0	($0.02)	($0.01)
Weighted-average shares of Common Stock outstanding	60,938,316	56,676,166	60,260,456	56,676,166

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014	Jul. 31, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Net loss	($565,627)	($317,232)	($1,313,769)	($761,619)
Net loss attributable to non-controlling interest	'	-1,804	'	-4,525
Net loss attributable to Cardiogenics Holdings Inc.	-565,627	-315,428	-1,313,769	-757,094
Other comprehensive income (loss), currency translation adjustments	-10,262	20,798	66,415	30,308
Comprehensive loss	($575,889)	($294,630)	($1,247,354)	($726,786)

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Changes in Deficiency (Unaudited) (USD $)	3 Months Ended	9 Months Ended
	Jul. 31, 2014	Jul. 31, 2014
Balance	'	($917,044)
Issuance of common shares on conversion of notes payable January 2014	'	12,067
Issuance of warrants on settlement of suit January 2014	'	189,000
Issuance of common shares for cash January 2014 at $0.25	'	50,000
Issuance of common shares on conversion of shares of subsidiary	'	'
Issuance of common shares on conversion of notes payable February 2014	'	18,559
Issuance of common shares on conversion of notes payable March 2014	'	14,895
Issuance of common shares on conversion of notes payable April 2014	'	12,480
Issuance of common shares for services rendered March 2014	'	17,917
Issuance of common shares for services rendered April 2014	'	7,083
Issuance of common shares on conversion of notes payable May 2014	'	15,500
Settlement of derivative value of notes payable on conversion to common shares	'	98,276
Net Loss	-565,627	-1,313,769
Other Comprehensive Income	'	'
Currency Translation Adjustment	-10,262	66,415
Total Comprehensive Income (Loss)	-575,889	-1,247,354
Balance	-1,728,621	-1,728,621
Common Stock [Member]	'	'
Balance	'	565
Balance, shares	'	58,903,595
Issuance of common shares on conversion of notes payable January 2014	'	1
Issuance of common shares on conversion of notes payable January 2014, shares	'	100,000
Issuance of warrants on settlement of suit January 2014	'	7
Issuance of warrants on settlement of suit January 2014, shares	'	700,000
Issuance of common shares for cash January 2014 at $0.25	'	2
Issuance of common shares for cash January 2014 at $0.25, shares	'	200,000
Issuance of common shares on conversion of shares of subsidiary	'	3
Issuance of common shares on conversion of shares of subsidiary, shares	'	296,538
Issuance of common shares on conversion of notes payable February 2014	'	2
Issuance of common shares on conversion of notes payable February 2014, shares	'	154,658
Issuance of common shares on conversion of notes payable March 2014	'	1
Issuance of common shares on conversion of notes payable March 2014, shares	'	150,000
Issuance of common shares on conversion of notes payable April 2014	'	2
Issuance of common shares on conversion of notes payable April 2014, shares	'	160,000
Issuance of common shares for services rendered March 2014	'	1
Issuance of common shares for services rendered March 2014, shares	'	83,333
Issuance of common shares for services rendered April 2014	'	0
Issuance of common shares for services rendered April 2014, shares	'	32,946
Issuance of common shares on conversion of notes payable May 2014	'	3
Issuance of common shares on conversion of notes payable May 2014, shares	'	258,333
Other Comprehensive Income	'	'
Balance	587	587
Balance, shares	61,039,403	61,039,403
Additional Paid-In Capital [Member]	'	'
Balance	'	44,514,000
Issuance of common shares on conversion of notes payable January 2014	'	12,066
Issuance of warrants on settlement of suit January 2014	'	188,993
Issuance of common shares for cash January 2014 at $0.25	'	49,998
Issuance of common shares on conversion of shares of subsidiary	'	-356,227
Issuance of common shares on conversion of notes payable February 2014	'	18,557
Issuance of common shares on conversion of notes payable March 2014	'	14,894
Issuance of common shares on conversion of notes payable April 2014	'	12,478
Issuance of common shares for services rendered March 2014	'	17,916
Issuance of common shares for services rendered April 2014	'	7,083
Issuance of common shares on conversion of notes payable May 2014	'	15,497
Settlement of derivative value of notes payable on conversion to common shares	'	98,276
Other Comprehensive Income	'	'
Balance	44,593,531	44,593,531
Accumulated Deficit [Member]	'	'
Balance	'	-44,957,870
Net Loss	'	-1,313,769
Other Comprehensive Income	'	'
Total Comprehensive Income (Loss)	'	-1,313,769
Balance	-46,271,639	-46,271,639
Accumulated Other Comprehensive Income (Loss) [Member]	'	'
Balance	'	-117,515
Other Comprehensive Income	'	'
Currency Translation Adjustment	'	66,415
Total Comprehensive Income (Loss)	'	66,415
Balance	-51,100	-51,100
Noncontrolling Interest [Member]	'	'
Balance	'	-356,224
Issuance of common shares on conversion of shares of subsidiary	'	356,224
Other Comprehensive Income	'	'
Balance	'	'

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Changes in Deficiency (Parenthetical) (USD $)	9 Months Ended
	Jul. 31, 2014
Statement of Stockholders' Equity [Abstract]	'
Equity price per share	$0.25

Condensed_Consolidated_Stateme4

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
	Jul. 31, 2014	Jul. 31, 2013
Cash flows from operating activities	'	'
Consolidated Net Loss	($1,313,769)	($761,619)
Adjustments to reconcile consolidated net loss to net cash used in operating activities	'	'
Depreciation and Amortization of Property and Equipment	8,168	10,341
Amortization of Patent Application Costs	5,140	5,089
Loss (Gain) on Change in Value of Derivative Liability	247,249	-7,250
Amortization of Discount on Notes Payable	123,521	45,685
Amortization of Discount on Debentures Payable	186,489	49,532
Common Stock Issued for Services Rendered	25,000	'
Changes in Operating Assets and Liabilities, Net of Acquisition	'	'
Accounts Receivable	10	187
Deposits and Prepaid Expenses	2,094	1,411
Refundable Taxes Receivable	-580	40,419
Government Grants and Investment Tax Credits Receivable	-11,218	21,669
Accounts Payable and Accrued Expenses	186,909	-28,897
Net cash used in operating activities	-540,987	-623,433
Cash flows from investing activities	'	'
Purchase of Property and Equipment	'	-154
Patent Application Costs	'	-8,923
Net cash used in investing activities	'	-9,077
Cash flows from financing activities	'	'
Due to Shareholders	22,957	-100,000
Proceeds from Notes Payable	180,000	100,000
(Repayment) of Capital Lease Obligations	'	-2,627
Issue of Common Shares for Cash	50,000	'
Issue (Redemption) of 10% Senior Convertible Debentures	'	945,600
Net cash provided by financing activities	252,957	942,973
Effect of foreign exchange on cash and cash equivalents	39,284	20,130
Cash and Cash Equivalents	'	'
Increase (decrease) in cash and cash equivalents during the period	-248,746	330,593
Beginning of Period	263,103	27,009
End of Period	$14,357	$357,602

Condensed_Consolidated_Stateme5

Condensed Consolidated Statements of Cash Flows (Parenthetical)	9 Months Ended
	Jul. 31, 2013
Statement of Cash Flows [Abstract]	'
Senior Convertible Debentures, interest rate	10.00%

Nature_of_Business

Nature of Business	9 Months Ended
	Jul. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Nature of Business	'
	1	Nature of Business
	CardioGenics Inc. (“CardioGenics”) was incorporated on November 20, 1997 in the Province of Ontario, Canada, and carries on the business of development and commercialization of diagnostic test products to the In Vitro Diagnostics testing market. CardioGenics has several test products that are in various stages of development.
	CardioGenics’ business has a limited history of operations and whose revenues, to date, have been primarily comprised of grant revenue and Scientific Research Tax Credits from government agencies. There can be no assurance that the Company will be successful in obtaining regulatory approval for the marketing of any of the existing or future products that the Company will succeed in developing.
	On October 27, 2009, the name of the Company was changed from JAG Media Holdings, Inc. to CardioGenics Holdings, Inc.

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Jul. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of Presentation	'
	2	Basis of Presentation
	In the opinion of management, the unaudited condensed interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary to present fairly the condensed interim consolidated financial position of CardioGenics Holdings, Inc. and its subsidiaries under generally accepted accounting principles in the United States (“US GAAP”) as of July 31, 2014, their results of operations for the three and nine months ended July 31, 2014 and 2013, changes in deficiency for the nine months ended July 31, 2014 and cash flows for the nine months ended July 31, 2014 and 2013. CardioGenics Holdings, Inc. and its subsidiaries are referred to together herein as the “Company”. Pursuant to rules and regulations of the SEC, certain information and disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted from these consolidated financial statements unless significant changes have taken place since the end of the most recent fiscal year. Accordingly, these condensed interim consolidated financial statements should be read in conjunction with the consolidated financial statements, notes to consolidated financial statements and the other information in the audited consolidated financial statements of the Company as of October 31, 2013 and 2012 (the “Audited Financial Statements”) included in the Company’s Form 10-K that was previously filed with the SEC on February 13, 2014 and from which the October 31, 2013 consolidated balance sheet was derived.
	The results of the Company’s operations for the nine months ended July 31, 2014 are not necessarily indicative of the results of operations to be expected for the full year ending October 31, 2014.
	The accompanying condensed interim consolidated financial statements have been prepared using the accounting principles generally accepted in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.
	The Company has incurred operating losses and has experienced negative cash flows from operations since inception. The Company has an accumulated deficit at July 31, 2014 of approximately $46.3 million. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. The Company has funded its activities to date almost exclusively from debt and equity financings. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.
	The Company will continue to require substantial funds to continue research and development, including preclinical studies and clinical trials of its products, and to commence sales and marketing efforts, if the FDA and other regulatory approvals are obtained. In order to meet its operating cash flow requirements management’s plans include financing activities such as private placements of its common stock and issuances of convertible debt instruments. Management is also actively pursuing industry collaboration activities including product licensing and specific project financing.
	While the Company believes it will be successful in obtaining the necessary financing to fund its operations, meet revenue projections and manage costs, there are no assurances that such additional funding will be achieved and that it will succeed in its future operations. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might be necessary should the Company be unable to continue in existence.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Jul. 31, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	3	Summary of Significant Accounting Policies.
	Derivative Instruments
	The Company’s derivative liabilities are related to embedded conversion features of the Notes Payable. For derivative instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in fair value recognized in earnings each reporting period. The Company uses the Black-Scholes model to value the derivative instruments at inception and subsequent valuation dates and the value is re-assessed at the end of each reporting period, in accordance with Accounting Standards Codification (“ASC”) 815. Derivative instrument liabilities are classified in the consolidated balance sheets as current or non-current based on whether or not the net-cash settlement of the derivative instrument could be required within twelve months of the consolidated balance sheet date.
	Beneficial Conversion Charge
	The intrinsic value of beneficial conversion features arising from the issuance of convertible debentures with conversion rights that are in-the-money at the commitment date is recorded as debt discount and amortized to interest expense over the term of the debentures. The intrinsic value of a beneficial conversion feature is determined after initially allocating an appropriate portion of the proceeds received from the sale of the debentures to any detachable instruments, such as warrants, included in the sale or exchange based on relative fair values.
	Recently Issued Accounting Standards
	Revenue From Contracts With Customers
	In May 2014, the FASB issued an update to ASC 606, Revenue from Contracts with Customers. This update to ASC 606 provides a five-step process to determine when and how revenue is recognized. The core principle of the guidance is that a Company should recognize revenue upon transfer of promised goods or services to customers in an amount that reflects the expected consideration to be received in exchange for those goods and services. This update to ASC 606 will also result in enhanced disclosures about revenue, providing guidance for transactions that were not previously addressed comprehensively, and improving guidance for multiple-element arrangements. This update to ASC 606 is effective for the Company beginning in fiscal 2017. The Company is currently evaluating the impact of this update on its consolidated financial statements.
	Development Stage Entities: Elimination of Certain Financial Reporting Requirements
	On June 10, 2014, FASB issued Accounting Standards Update No. 2014-10, Development Stage Entities: Elimination of Certain Financial Reporting Requirements. The update removes the definition of a development stage entity from FASB ASC 915 and eliminates the requirement for development stage entities to present inception-to-date information on the statements of operations, cash flows and stockholders’ equity. The Company already adopted this standard for the period covered by the report herein.
	Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to the consolidated financial statements of the Company.

Income_Taxes

Income Taxes	9 Months Ended
	Jul. 31, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	4	Income Taxes
	Based on the Company’s evaluation, management has concluded that there are no significant tax positions requiring recognition in the condensed interim consolidated financial statements.
	The Company has incurred losses in Canada since inception, which have generated net operating loss carryforwards for income tax purposes. The net operating loss carryforwards arising from Canadian sources as of July 31, 2014, approximated $9,789,000 (2013 - $6,816,000) which will expire from 2015 through 2033. All fiscal years as originally filed have been assessed. Claims relating to research and development credits are open for review for the fiscal years ended October 2013, 2012, 2011, 2010, 2009, 2008 and 2007 and July 2009.
	As of July 31, 2014, the Company had net operating loss carryforwards from US sources of approximately $41,686,000 (2012 - $40,809,000) available to reduce future Federal taxable income which will expire from 2020 through 2033. Returns for the years 2008 through 2013 are yet to be filed.
	For the nine months ended July 31, 2014 and 2013, the Company’s effective tax rate differs from the statutory rate principally due to the net operating losses for which no benefit was recorded.

Due_to_Shareholder

Due to Shareholder	9 Months Ended
	Jul. 31, 2014
Notes to Financial Statements	'
Due to Shareholder	'
	5	Due to Shareholder
	During the year a shareholder/officer advanced $22,957 to the Company. The advance carries no interest and is due on demand.

Notes_Payable

Notes Payable	9 Months Ended
	Jul. 31, 2014
Notes Payable [Abstract]	'
Notes Payable	'
	6	Notes Payable
	On November 19, 2012 the Company entered into an agreement (“Line”) with JMJ Financial (“Lender”) whereby the Company may borrow up to $350,000. The Line is subject to an original issue discount of $50,000. Advances under the Line (“JMJ Notes”) have a maturity date of one year from the date of the advance. If the advance is repaid within three months the advance is interest free. If not repaid within three months, the advance may not be repaid before maturity and carries interest at 5%. The Lender has the right at any time to convert all or part of the outstanding principal and accrued interest (and any other fees) into shares of fully paid and non-assessable shares of common stock of the Company at a price equal to the lesser of $0.23 and 60% of the lowest trade price in the 25 trading days previous to the conversion. Unless agreed in writing by the parties, at no time will the Lender convert any amount owing under the Line into common stock that would result in the Lender owing more than 4.99% of the common stock outstanding. During the year nine months the Company drew $75,000 under the Line.
	On May 23, 2014 the Company issued promissory notes (the “LG Notes”) to LG Capital Funding, LLC and Adar Bays, LLC (collectively the “Holders”) in the amount of $52,500 each bearing interest at 8% annually due May 23, 2015. The LG Notes and accrued interest may be converted into shares of the Common Stock of the Company at a 42% discount to the lowest closing bid with a 12 day look back. The LG Notes may be prepaid with the following penalties: (i) if the Notes are prepaid within 60 days of the issue date, then at 130% of the face amount plus any accrued interest; and, (ii) if the LG Notes are prepaid after 60 days after the issue date but less than 181 days after the issue date, then at 140% of the face amount plus any accrued interest. The LG Notes may not be prepaid after the 180th day after issue.
	A summary of the Notes is as follows:
			31-Jul-14			31-Oct-13
	Convertible Note Payable, due June 27, 2014		$	-		$	25,000
	Convertible Note Payable, due September 26, 2014			-			35,000
	Convertible Note Payable, due February 20, 2015			35,000			-
	Convertible Notes Payable, due May 23, 2015			105,000			-
	Convertible Note Payable, due June 23, 2015			40,000			-
	Debt Discount - value attributable to conversion feature attached to notes, net of accumulated amortization of $41,206 and $11,983			(138,794	)		(48,017	)
	Total			41,206			11,983
	Less: Current portion			41,206			11,983
	Total Long-term portion		$	-		$	-
	As described in further detail in Note 7, “Derivative Liabilities”, the Company determines the fair value of the embedded derivatives and records them as a discount to the Notes and as a derivative liability. The discount to the Notes is amortized to Loss (Gain) in Change in Value of Derivative Liability over the life of the Note or until conversion. The amount charged to Loss (Gain) in Change in Value of Derivative Liability for the three and nine months was $246,430 and $247,249 respectively. Upon conversion of the Notes and related interest and original issue discount to Common Stock, any remaining unamortized discount is charged to financing expense. During the three and nine months, Notes in the principal amount of $12,653 and $60,000 respectively plus interest and original issue discount totaling $2,847 and $13,501 respectively were exchanged for 258,333 and 822,991 common shares respectively.

Derivative_Liabilities

Derivative Liabilities	9 Months Ended
	Jul. 31, 2014
Derivative Liability [Abstract]	'
Derivative Liabilities	'
	7	Derivative Liabilities
	Convertible notes - embedded conversion features:
	The JMJ Notes and the LG Notes meet the definition of a hybrid instrument, as defined in Accounting Standard Codification (ASC) 815. The hybrid instrument is comprised of a i) a debt instrument, as the host contract and ii) an option to convert the debentures into common stock of the Company, as an embedded derivative. The embedded derivatives derive their value based on the underlying fair value of the Company’s common stock. The embedded derivatives are not clearly and closely related to the underlying host debt instrument since the economic characteristics and risk associated with these derivatives are based on the common stock fair value.
	The Company determines the fair value of the embedded derivatives and records them as a discount to the Notes and a derivative liability. The Company has recognized a derivative liability of $428,675 and $99,702 at July 31, 2014 and October 31, 2013, respectively. Accordingly, changes in the fair value of the embedded derivative are immediately recognized in earnings and classified as a gain or loss on the embedded derivative financial instrument in the accompanying statements of operations.
	The Company estimated the fair value of the embedded derivatives in the JMJ Notes using a Black Scholes model with the following assumptions: conversion price $0.06 per share according to the agreements; risk free interest rate of .11%; expected life of .53-.85 year; expected dividend of zero; a volatility factor of 187%-214%, as of July 31, 2014. The Company estimated the fair value of the embedded derivatives in the LG Notes using a Black Scholes model with the following assumptions: conversion price $0.058 per share according to the agreements; risk free interest rate of .11%; expected life of .81 year; expected dividend of zero; a volatility factor of 205%, as of July 31, 2014. The expected lives of the instruments are equal to the contractual term of the conversion option. The expected volatility is based on the historical price volatility of the Company’s common stock. The risk-free interest rate represents the U.S. Treasury constant maturities rate for the expected life of the related conversion option. The dividend yield represents anticipated cash dividends to be paid over the expected life of the conversion option.

Fair_Value_Measurements

Fair Value Measurements

9 Months Ended

Jul. 31, 2014

Fair Value Disclosures [Abstract]

'

Fair Value Measurements

'

8

Fair Value Measurements

As defined by the ASC, fair value measurements and disclosures establish a hierarchy that prioritizes fair value measurements based on the type of inputs used for the various valuation techniques (market approach, income approach and cost approach). The levels of hierarchy are described below:

●

Level 1:  Observable inputs such as quoted market prices in active markets for identical assets or liabilities.

●

Level 2:  Inputs other than quoted market prices that are observable for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets, such as interest rates and yield curves that are observable at commonly-quoted intervals.

●

Level 3:  Unobservable inputs that reflect the reporting entity’s own assumptions, as there is little, if any, related market activity.

The following table summarizes the financial liabilities measured at fair value on a recurring basis as of July 31, 2014, segregated by the level of the valuation inputs within the fair value hierarchy utilized to measure fair value:

Quoted Prices in

Total Increase (Reduction)

Active Markets for

Significant Other

Significant

in Fair Value

Balance Sheet

Identical Assets or

Observable Inputs

Unobservable

31-Jul-14

Recorded at

Location

Liabilities (Level 1)

(Level 2)

Inputs (Level 3)

Total

31-Jul-14

Liabilities:

Derivative liability – on Notes Payable

$

-

$

-

$

428,675

$

428,675

$

247,249

The table below sets forth a summary of changes in the fair value of the Company’s Level 3 financial liability, or derivative liabilities related to the senior secured convertible notes and warrants, for the nine months ended July 31, 2014:

Balance at beginning of period

$

99,702

Additions to derivative instruments

180,000

Change in fair value of derivative liabilities

247,249

Settlements

(98,276

)

Balance at end of period

$

428,675

Debentures_Payable

Debentures Payable	9 Months Ended
	Jul. 31, 2014
Debt Disclosure [Abstract]	'
Debentures Payable	'
	9	Debentures Payable
	In February 2013, shareholder loans were converted on a dollar-for-dollar basis for Series A Convertible Debenture Units (the “A Units”). Each A Unit includes a debenture having a term of three years, bearing interest at 10%, and a warrant having a term of three years. The debentures are convertible at any time into common shares of the Company’s stock at a price of $0.25 per share. The warrants entitle the holder to purchase 2 times the number of common shares of the Company’s stock allowed in conjunction with the debentures at any time up to three years.
	A summary of the Debentures is as follows:
			31-Jul-14			31-Oct-13
	Series A Convertible Debentures Payable, interest at 10% per annum to maturity at February 27, 2016		$	283,355		$	288,584
	Series B Convertible Debentures Payable, interest at 10% per annum to maturity at May 31, 2016			500,000			500,000
	Series B Convertible Debentures Payable, interest at 10% per annum to maturity at June 3, 2016			142,086			148,653
	Debt Discount - value attributable to conversion feature attached to notes			(447,558	)		(634,047	)
	Total			477,883			303,190
	Less: Current portion			-			-
	Total Long-term portion		$	477,883		$	303,190
	Debt discount is amortized to interest expense over the life of the debentures. The amount amortized to interest expense for the period was $186,489.
	On May 15, 2014, the Company received a notice of default (the “Default Notice”) from the debenture holder under Convertible Debenture No. SBCD-01, dated May 31, 2013 in the original principal amount of $500,000 (the “Debenture”), for failure to make the required interest payments under the Debenture.
	On June 1, 2014, the Debenture holder and the Company entered into a Standstill and Debt Conversion Agreement (the “Standstill Agreement”) pursuant to which the Debenture holder agreed to (i) refrain from exercising or enforcing any right or remedy against the Company in connection with the Debenture and the Default Notice during a “Standstill Period,” which expired on July 31, 2014 and (ii) convert $350,000 in principal of the Debenture into common stock of the Company at a conversion price equal to the “per share price” of an offering of the Company’s common stock involving Polish investors that was pending at the time, if and when such offering closed (the “Polish Offering”). In consideration for the Debenture holder’s forbearance and conversion obligations, the Company agreed to (i) pay the Debenture holder $150,000 in principal under the Debenture, and accrued interest as of the payment date, from the proceeds of the Polish Offering, if and when the Polish Offering closed. As the Polish Offering was terminated by the Company’s investment bankers prior to July 31, 2014, the Standstill Agreement expired by its terms on July 31, 2014.
	On September 16, 2014, the Debenture holder and the Company agreed upon a final settlement, pursuant to which the Debenture holder would convert all accrued and unpaid interest, as well as all unpaid principal under the Debenture, into 5,507,979 shares of the Company’s common stock.

Stock_Based_Compensation

Stock Based Compensation	9 Months Ended
	Jul. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock Based Compensation	'
	10	Stock Based Compensation
	Stock-based employee compensation related to stock options for the nine months ended July 31, 2014 and 2013 amounted to $-0-.
	The following is a summary of the common stock options outstanding, granted, forfeited or expired and exercised under the Plan:
					Average
					Exercise
			Options		Price
	Outstanding – October 31, 2012			30,000	$	0.9
	Granted			—		—
	Forfeited/Expired			—		—
	Exercised			—		—
	Outstanding – October 31, 2013			30,000	$	0.9
	Granted			—		—
	Forfeited/Expired			—		—
	Exercised			—		—
	Outstanding – July 31, 2014			30,000	$	0.9
	Options typically vest immediately at the date of grant. As such, the Company does not have any unvested options or unrecognized compensation expense at July 31, 2014.

Warrants

Warrants	9 Months Ended
	Jul. 31, 2014
Stockholders' Equity Note [Abstract]	'
Warrants	'
	11	Warrants
	Outstanding warrants are as follows:
			31-Jul-14		31-Oct-13
	Issued to Flow Capital Advisors Inc. on settlement of lawsuit in August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.30 per common share up to and including August 23, 2016			250,000		250,000
	Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.50 per common share up to and including August 23, 2016			250,000		250,000
	Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.75 per common share up to and including August 23, 2016			500,000		500,000
	Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $1.00 per common share up to and including August 23, 2016			500,000		500,000
	Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.75 per common share up to and including August 23, 2016			500,000		500,000
	Issued to debenture holders February 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.25 per common share up to and including February 27, 2016			600,000		600,000
	Issued to debenture holders May 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including June 3, 2016			750,000		750,000
	Issued to debenture holders June 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including June 3, 2016			232,500		232,500
	Issued to consultants on August 5, 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including August 4, 2023			2,500,000		2,500,000
	Issued to consultants on August 5, 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.10 per common share up to and including August 4, 2023			1,500,000		1,500,000
	Issued to consultant on September 3, 2013 entitling the holder to purchase 1 common share in the Company at an exercise price of $0.50 per common share up to and including July 31, 2018			500,000		500,000
	Issued to shareholder on October 29, 2013 entitling the holder to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including October 29, 2016			250,000		250,000
	Issued to shareholder on November 7, 2013 entitling the holder to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including November 7, 2016			125,000		-
	Total Warrants outstanding			8,457,500		8,332,500

Issuance_of_Common_Stock

Issuance of Common Stock	9 Months Ended
	Jul. 31, 2014
Stockholders' Equity Note [Abstract]	'
Issuance of Common Stock	'
	12	Issuance of Common Stock
	During the nine months ended July 31, 2014, the Company issued the following common shares:
	Issued for services rendered		116,279
	Issued to shareholder for cash at $0.25 per share		200,000
	Issued on conversion of notes payable		822,991
	Issued on settlement of suit		700,000
	Issued to minority shareholders on conversion of subsidiary’s shares		296,538
			2,135,808

Net_Loss_per_Share

Net Loss per Share	9 Months Ended
	Jul. 31, 2014
Earnings Per Share [Abstract]	'
Net Loss per Share	'
	13	Net Loss per Share
	The following table sets forth the computation of weighted-average shares outstanding for calculating basic and diluted earnings per share (EPS):
			Three Months Ended				Nine Months Ended
			July 31,				July 31,
			2014		2013		2014		2013
	Weighted-average shares - basic			60,938,316		56,676,166		60,260,456		56,676,166
	Effect of dilutive securities			—		—		—		—
	Weighted-average shares - diluted			60,938,316		56,676,166		60,260,456		56,676,166
	Basic earnings per share “EPS” and diluted EPS for the three and nine months ended July 31, 2014 and 2013 have been computed by dividing the net loss available to common stockholders for each respective period by the weighted average shares outstanding during that period. All outstanding options, warrants and shares to be issued upon the exercise of the outstanding options and warrants and conversion of debt representing 15,367,845 and 8,532,918 incremental shares, respectively, have been excluded from the three and nine months ended July 31, 2014 and 2013 computation of diluted EPS as they are antidilutive given the net losses generated.

Supplemental_Disclosure_of_Cas

Supplemental Disclosure of Cash Flow Information	9 Months Ended
	Jul. 31, 2014
Supplemental Cash Flow Elements [Abstract]	'
Supplemental Disclosure of Cash Flow Information	'
	14	Supplemental Disclosure of Cash Flow Information
			For the Nine Months Ended
			31-Jul
			2014		2013
	Cash paid during the year for:
	Interest		$	12,352	$	26,085
	Income taxes		$	—	$	—
	Non-cash financing activities
	Conversion of notes payable		$	73,501	$	—
	Settlement of derivative liability		$	98,276	$	—
	Issuance of shares on settlement of suit		$	189,000	$	—

Commitments_and_Contingent_Lia

Commitments and Contingent Liabilities	9 Months Ended
	Jul. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingent Liabilities	'
	15	Commitments and Contingent Liabilities
		Lawsuit
	On April 22, 2009, the Company was served with a statement of claim from a former employee claiming compensation for wrongful dismissal and ancillary causes of action including payment of monies in realization of his investment in the Company, with an aggregate claim of $514,000. On January 3, 2014 the suit was settled for cash consideration of $10,000 plus 700,000 common shares.

Subsequent_Events

Subsequent Events	9 Months Ended
	Jul. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	16	Subsequent Events
		a.	In August 2014, $15,000 in principal amount of JMJ notes payable were converted to 250,000 common shares of the Company.
		b.	In September 2014, an officer of the Company advanced $9,183 to the Company.
		c.	On September 17, 2014, Convertible Debenture No. SBCD-01 dated May 31, 2013 in the Original Principal Amount of $500,000 and all accrued interest ($50,797.87), representing all amounts owing to the Debenture holder, were converted into 5,507,253 Common Shares of the Company stock.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Jul. 31, 2014
Accounting Policies [Abstract]	'
Derivative Instruments	'
	Derivative Instruments
	The Company’s derivative liabilities are related to embedded conversion features of the Notes Payable. For derivative instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in fair value recognized in earnings each reporting period. The Company uses the Black-Scholes model to value the derivative instruments at inception and subsequent valuation dates and the value is re-assessed at the end of each reporting period, in accordance with Accounting Standards Codification (“ASC”) 815. Derivative instrument liabilities are classified in the consolidated balance sheets as current or non-current based on whether or not the net-cash settlement of the derivative instrument could be required within twelve months of the consolidated balance sheet date.
Beneficial Conversion Charge	'
	Beneficial Conversion Charge
	The intrinsic value of beneficial conversion features arising from the issuance of convertible debentures with conversion rights that are in-the-money at the commitment date is recorded as debt discount and amortized to interest expense over the term of the debentures. The intrinsic value of a beneficial conversion feature is determined after initially allocating an appropriate portion of the proceeds received from the sale of the debentures to any detachable instruments, such as warrants, included in the sale or exchange based on relative fair values.
Recently Issued Accounting Standards	'
	Recently Issued Accounting Standards
	Revenue From Contracts With Customers
	In May 2014, the FASB issued an update to ASC 606, Revenue from Contracts with Customers. This update to ASC 606 provides a five-step process to determine when and how revenue is recognized. The core principle of the guidance is that a Company should recognize revenue upon transfer of promised goods or services to customers in an amount that reflects the expected consideration to be received in exchange for those goods and services. This update to ASC 606 will also result in enhanced disclosures about revenue, providing guidance for transactions that were not previously addressed comprehensively, and improving guidance for multiple-element arrangements. This update to ASC 606 is effective for the Company beginning in fiscal 2017. The Company is currently evaluating the impact of this update on its consolidated financial statements.
	Development Stage Entities: Elimination of Certain Financial Reporting Requirements
	On June 10, 2014, FASB issued Accounting Standards Update No. 2014-10, Development Stage Entities: Elimination of Certain Financial Reporting Requirements. The update removes the definition of a development stage entity from FASB ASC 915 and eliminates the requirement for development stage entities to present inception-to-date information on the statements of operations, cash flows and stockholders’ equity. The Company already adopted this standard for the period covered by the report herein.
	Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to the consolidated financial statements of the Company.

Notes_Payable_Tables

Notes Payable (Tables)	9 Months Ended
	Jul. 31, 2014
Notes Payable [Abstract]	'
Summary of Notes Payable	'
	A summary of the Notes is as follows:
		31-Jul-14			31-Oct-13
	Convertible Note Payable, due June 27, 2014	$	-		$	25,000
	Convertible Note Payable, due September 26, 2014		-			35,000
	Convertible Note Payable, due February 20, 2015		35,000			-
	Convertible Notes Payable, due May 23, 2015		105,000			-
	Convertible Note Payable, due June 23, 2015		40,000			-
	Debt Discount - value attributable to conversion feature attached to notes, net of accumulated amortization of $41,206 and $11,983		(138,794	)		(48,017	)
	Total		41,206			11,983
	Less: Current portion		41,206			11,983
	Total Long-term portion	$	-		$	-

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)

9 Months Ended

Jul. 31, 2014

Fair Value Disclosures [Abstract]

'

Schedule of Fair Value of Liabilities Measured on Recurring Basis

'

The following table summarizes the financial liabilities measured at fair value on a recurring basis as of July 31, 2014, segregated by the level of the valuation inputs within the fair value hierarchy utilized to measure fair value:

Quoted Prices in

Total Increase (Reduction)

Active Markets for

Significant Other

Significant

in Fair Value

Balance Sheet

Identical Assets or

Observable Inputs

Unobservable

31-Jul-14

Recorded at

Location

Liabilities (Level 1)

(Level 2)

Inputs (Level 3)

Total

31-Jul-14

Liabilities:

Derivative liability – on Notes Payable

$

-

$

-

$

428,675

$

428,675

$

247,249

Schedule of Changes in Fair Value of Financial Liabilities or Derivative Liabilities

'

The table below sets forth a summary of changes in the fair value of the Company’s Level 3 financial liability, or derivative liabilities related to the senior secured convertible notes and warrants, for the nine months ended July 31, 2014:

Balance at beginning of period

$

99,702

Additions to derivative instruments

180,000

Change in fair value of derivative liabilities

247,249

Settlements

(98,276

)

Balance at end of period

$

428,675

Debentures_Payable_Tables

Debentures Payable (Tables)	9 Months Ended
	Jul. 31, 2014
Debt Disclosure [Abstract]	'
Schedule of Debenture Payable	'
	A summary of the Debentures is as follows:
		31-Jul-14			31-Oct-13
	Series A Convertible Debentures Payable, interest at 10% per annum to maturity at February 27, 2016	$	283,355		$	288,584
	Series B Convertible Debentures Payable, interest at 10% per annum to maturity at May 31, 2016		500,000			500,000
	Series B Convertible Debentures Payable, interest at 10% per annum to maturity at June 3, 2016		142,086			148,653
	Debt Discount - value attributable to conversion feature attached to notes		(447,558	)		(634,047	)
	Total		477,883			303,190
	Less: Current portion		-			-
	Total Long-term portion	$	477,883		$	303,190

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
	Jul. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Compensation, Stock Options Activity	'
	The following is a summary of the common stock options outstanding, granted, forfeited or expired and exercised under the Plan:
				Average
				Exercise
		Options		Price
	Outstanding – October 31, 2012		30,000	$	0.9
	Granted		—		—
	Forfeited/Expired		—		—
	Exercised		—		—
	Outstanding – October 31, 2013		30,000	$	0.9
	Granted		—		—
	Forfeited/Expired		—		—
	Exercised		—		—
	Outstanding – July 31, 2014		30,000	$	0.9

Warrants_Tables

Warrants (Tables)	9 Months Ended
	Jul. 31, 2014
Stockholders' Equity Note [Abstract]	'
Schedule of Warrants Outstanding	'
	Outstanding warrants are as follows:
		31-Jul-14		31-Oct-13
	Issued to Flow Capital Advisors Inc. on settlement of lawsuit in August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.30 per common share up to and including August 23, 2016		250,000		250,000
	Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.50 per common share up to and including August 23, 2016		250,000		250,000
	Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.75 per common share up to and including August 23, 2016		500,000		500,000
	Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $1.00 per common share up to and including August 23, 2016		500,000		500,000
	Issued to Flow Capital Advisors Inc. on settlement of lawsuit August 2011, entitling the holder to purchase 1 common share in the Company at an exercise price of $0.75 per common share up to and including August 23, 2016		500,000		500,000
	Issued to debenture holders February 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.25 per common share up to and including February 27, 2016		600,000		600,000
	Issued to debenture holders May 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including June 3, 2016		750,000		750,000
	Issued to debenture holders June 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including June 3, 2016		232,500		232,500
	Issued to consultants on August 5, 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including August 4, 2023		2,500,000		2,500,000
	Issued to consultants on August 5, 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.10 per common share up to and including August 4, 2023		1,500,000		1,500,000
	Issued to consultant on September 3, 2013 entitling the holder to purchase 1 common share in the Company at an exercise price of $0.50 per common share up to and including July 31, 2018		500,000		500,000
	Issued to shareholder on October 29, 2013 entitling the holder to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including October 29, 2016		250,000		250,000
	Issued to shareholder on November 7, 2013 entitling the holder to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including November 7, 2016		125,000		-
	Total Warrants outstanding		8,457,500		8,332,500

Issuance_of_Common_Stock_Table

Issuance of Common Stock (Tables)	9 Months Ended
	Jul. 31, 2014
Stockholders' Equity Note [Abstract]	'
Schedule of Common Stock Issue	'
	During the nine months ended July 31, 2014, the Company issued the following common shares:
	Issued for services rendered	116,279
	Issued to shareholder for cash at $0.25 per share	200,000
	Issued on conversion of notes payable	822,991
	Issued on settlement of suit	700,000
	Issued to minority shareholders on conversion of subsidiary’s shares	296,538
		2,135,808

Net_Loss_per_Share_Tables

Net Loss per Share (Tables)	9 Months Ended
	Jul. 31, 2014
Earnings Per Share [Abstract]	'
Computation of Weighted Average Shares Outstanding for Calculating Basic and Diluted Earnings Per Share	'
	The following table sets forth the computation of weighted-average shares outstanding for calculating basic and diluted earnings per share (EPS):
		Three Months Ended				Nine Months Ended
		July 31,				July 31,
		2014		2013		2014		2013
	Weighted-average shares - basic		60,938,316		56,676,166		60,260,456		56,676,166
	Effect of dilutive securities		—		—		—		—
	Weighted-average shares - diluted		60,938,316		56,676,166		60,260,456		56,676,166

Supplemental_Disclosure_of_Cas1

Supplemental Disclosure of Cash Flow Information (Tables)	9 Months Ended
	Jul. 31, 2014
Supplemental Cash Flow Information [Abstract]	'
Cash Flow Supplemental Disclosures	'
		For the Nine Months Ended
		31-Jul
		2014		2013
	Cash paid during the year for:
	Interest	$	12,352	$	26,085
	Income taxes	$	—	$	—
	Non-cash financing activities
	Conversion of notes payable	$	73,501	$	—
	Settlement of derivative liability	$	98,276	$	—
	Issuance of shares on settlement of suit	$	189,000	$	—

Basis_of_Presentation_Details_

Basis of Presentation (Details Narrative) (USD $)	Jul. 31, 2014	Oct. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'	'
Accumulated deficit	$46,271,639	$44,957,870

Income_Taxes_Details_Narrative

Income Taxes (Details Narrative) (USD $)	9 Months Ended		9 Months Ended
	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014	Jul. 31, 2012
	CA [Member]	CA [Member]	U S [Member]	U S [Member]
Operating Loss Carryforwards [Line Items]	'	'	'	'
Net operating loss carry forwards	$9,789,000	$6,816,000	$41,686,000	$40,809,000
Operating loss carry forwards expiration period	'	'	'	'
	2015 through 2033		expire from 2020 through 2033.

Due_to_Shareholder_Details_Nar

Due to Shareholder (Details Narrative) (USD $)	Jul. 31, 2014
Notes to Financial Statements	'
Due to Shareholder	$22,957

Notes_Payable_Details_Narrativ

Notes Payable (Details Narrative) (USD $)	0 Months Ended		3 Months Ended		9 Months Ended		0 Months Ended
	Jun. 02, 2014	Nov. 19, 2012	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014	Jul. 31, 2013	23-May-14	23-May-14	Jul. 31, 2014
							LG Capital Funding, LLC and Adar Bays, LLC [Member]	LG Capital Funding [Member]	LG Capital Funding [Member]
NotesPayableLineItems [Line Items]	'	'	'	'	'	'	'	'	'
Line of credit facility, maximum borrowing capacity	'	$350,000	'	'	'	'	'	'	'
Line of credit facility original issue discount	'	50,000	'	'	'	'	'	'	'
Line of credit facility, interest rate during period	'	5.00%	'	'	'	'	'	'	'
Lenders right relating to notes payable description	'	'	'	'	'	'	'	'	'
		The Lender has the right at any time to convert all or part of the outstanding principal and accrued interest (and any other fees) into shares of fully paid and non-assessable shares of common stock of the Company at a price equal to the lesser of $0.23 and 60% of the lowest trade price in the 25 trading days previous to the conversion.
Conversion price per share	'	$0.23	$0.06	'	$0.06	'	'	'	$0.06
Percentage of lowest trading price of debt instrument on before conversion	'	60.00%	'	'	'	'	'	'	'
Line of credit facility common stock outstanding percentage	'	4.99%	'	'	'	'	'	'	'
Line of credit	'	75,000	'	'	'	'	'	'	'
Proceeds from issuance of promissory note	'	'	'	'	'	'	52,500	'	'
Debt instruments interest rate	'	'	'	'	'	'	8.00%	'	'
Debt instrument maturity Date	31-Jul-14	'	'	'	'	'	23-May-15	'	'
Debt converted into stock discount	'	'	'	'	'	'	'	42.00%	'
Debt penalities for issued date below 60 days	'	'	'	'	'	'	'	130.00%	'
Debt penalities for issued date After 60 days	'	'	'	'	'	'	'	140.00%	'
Loss (Gain) on Change in Fair Value of Derivative Liability	'	'	246,430	3,531	247,249	-7,250	'	'	'
Debt principle amount	'	'	12,653	'	60,000	'	'	'	'
Debt plus interest and original issue discount	'	'	$2,847	'	$13,501	'	'	'	'
Conversion of debt into common stock	'	'	258,333	'	822,991	'	'	'	'

Notes_Payable_Summary_of_Notes

Notes Payable - Summary of Notes Payable (Details) (USD $)	Jul. 31, 2014	Oct. 31, 2013
Short-term Debt [Line Items]	'	'
Debt Discount - value attributable to conversion feature attached to notes, net of accumulated amortization of $11,983	($138,794)	($48,017)
Total	41,206	11,983
Less: Current portion	41,206	11,983
Total Long-term portion	'	'
Convertible Note Payable, Due June 27, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Note Payable	'	25,000
Convertible Note Payable, Due September 26, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Note Payable	'	35,000
Convertible Note Payable, Due February 20, 2015 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Note Payable	35,000	'
Convertible Notes Payable, Due May 23, 2015 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Note Payable	105,000	'
Convertible Note Payable, Due June 23, 2015 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Note Payable	$40,000	'

Notes_Payable_Summary_of_Notes1

Notes Payable - Summary of Notes Payable (Details) (Parenthetical) (USD $)	0 Months Ended			9 Months Ended			12 Months Ended
	Jun. 02, 2014	Jul. 31, 2014	Oct. 31, 2013	Jul. 31, 2014	Jul. 31, 2014	Jul. 31, 2014	Oct. 31, 2013	Oct. 31, 2013
				Convertible Note Payable, Due February 20, 2015 [Member]	Convertible Notes Payable, Due May 23, 2015 [Member]	Convertible Note Payable, Due June 23, 2015 [Member]	Convertible Note Payable, Due June 27, 2014 [Member]	Convertible Note Payable, Due September 26, 2014 [Member]
Convertible Note Payable, maturity date	31-Jul-14	'	'	20-Feb-15	23-May-15	23-Jun-15	27-Jun-14	26-Sep-14
Net of accumulated amortization	'	$41,206	$11,983	'	'	'	'	'

Derivative_Liabilities_Details

Derivative Liabilities (Details Narrative) (USD $)	Jul. 31, 2014	Oct. 31, 2013	Nov. 19, 2012	Jul. 31, 2014	Jul. 31, 2014	Jul. 31, 2014	Jul. 31, 2014
				Lender [Member]	Lender [Member]	Lender [Member]	LG Capital Funding [Member]
					Minimum [Member]	Maximum [Member]
DerivativeLiabilitiesLineItems [Line Items]	'	'	'	'	'	'	'
Derivative liabilities	$428,675	$99,702	'	'	'	'	'
Conversion price per share	$0.06	'	$0.23	'	'	'	$0.06
Fair value assumptions, risk free interest rate	'	'	'	0.11%	'	'	0.11%
Fair value assumptions, expected term	'	'	'	'	'6 months 11 days	'10 months 6 days	'9 months 22 days
Fair value assumptions, expected dividend rate	'	'	'	0.00%	'	'	0.00%
Fair value assumptions, expected volatility rate	'	'	'	154.00%	'	'	205.00%

Fair_Value_Measurements_Schedu

Fair Value Measurements - Schedule of Fair Value of Liabilities Measured on Recurring Basis (Details) (USD $)	9 Months Ended
	Jul. 31, 2014	Oct. 31, 2013
Derivative liability on notes payable	$428,675	$99,702
Total Increase (Reduction) in Fair Value Recorded	247,249	'
Quoted Prices In Active Markets For Identical Assets Or Liabilities (Level 1) [Member]	'	'
Derivative liability on notes payable	'	'
Significant Other Observable Inputs (Level 2) [Member]	'	'
Derivative liability on notes payable	'	'
Significant Unobservable Inputs (Level 3) [Member]	'	'
Derivative liability on notes payable	$428,675	'

Fair_Value_Measurements_Schedu1

Fair Value Measurements - Schedule of Changes in Fair Value of Financial Liabilities or Derivative Liabilities (Details) (USD $)	9 Months Ended
	Jul. 31, 2014
Fair Value Disclosures [Abstract]	'
Balance at beginning of period	$99,702
Additions to derivative instruments	180,000
Change in fair value of derivative liabilities	247,249
Settlements	-98,276
Balance at end of period	$428,675

Debentures_Payable_Details_Nar

Debentures Payable (Details Narrative) (USD $)	0 Months Ended	9 Months Ended				1 Months Ended
	Jun. 02, 2014	Jul. 31, 2014	15-May-14	Oct. 31, 2013	Nov. 19, 2012	Feb. 28, 2013	Feb. 28, 2013
						Warrant [Member]	Series A Convertible Debenture [Member]
Short-term Debt [Line Items]	'	'	'	'	'	'	'
Debt instrument, interest rate terms	'	'	'	'	'	'	10.00%
Debt instrument term	'	'	'	'	'	'3 years	'3 years
Conversion price per share	'	$0.06	'	'	$0.23	'	$0.25
Debt Instrument, Redemption, Description	'	'	'	'	'	'	'
							The warrants entitle the holder to purchase 2 times the number of common shares of the Company’s stock allowed in conjunction with the debentures at any time up to three years.
Interest expense	'	$186,489	'	'	'	'	'
Debt instrument face amount	'	'	500,000	'	'	'	'
Convertible debt	350,000	477,883	'	303,190	'	'	'
Convertible Debentures Payable, maturity date	31-Jul-14	'	'	'	'	'	'
Payment to debenture holder	$150,000	'	'	'	'	'	'
Number of shares issued for conversion	5,507,979	'	'	'	'	'	'

Debentures_Payable_Schedule_of

Debentures Payable - Schedule of Debenture Payable (Details) (USD $)	Jul. 31, 2014	Jun. 02, 2014	Oct. 31, 2013
Short-term Debt [Line Items]	'	'	'
Debt Discount - value attributable to conversion feature attached to notes	($447,558)	'	($634,047)
Total	477,883	350,000	303,190
Less: Current portion	'	'	'
Total Long-term portion	477,883	'	303,190
Series A Convertible Debentures Payable, Maturity at February 27, 2016 [Member]	'	'	'
Short-term Debt [Line Items]	'	'	'
Convertible Debentures Payable	283,355	'	288,584
Series B Convertible Debentures Payable, Maturity at May 31, 2016 [Member]	'	'	'
Short-term Debt [Line Items]	'	'	'
Convertible Debentures Payable	500,000	'	500,000
Series B Convertible Debentures Payable, Maturity at June 3, 2016 [Member]	'	'	'
Short-term Debt [Line Items]	'	'	'
Convertible Debentures Payable	$142,086	'	$148,653

Debentures_Payable_Schedule_of1

Debentures Payable - Schedule of Debenture Payable (Details) (Parenthetical)	0 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended
	Jun. 02, 2014	Jul. 31, 2014	Oct. 31, 2013	Jul. 31, 2014	Oct. 31, 2013	Jul. 31, 2014	Oct. 31, 2013
		Series A Convertible Debentures Payable, Maturity at February 27, 2016 [Member]	Series A Convertible Debentures Payable, Maturity at February 27, 2016 [Member]	Series B Convertible Debentures Payable, Maturity at May 31, 2016 [Member]	Series B Convertible Debentures Payable, Maturity at May 31, 2016 [Member]	Series B Convertible Debentures Payable, Maturity at June 3, 2016 [Member]	Series B Convertible Debentures Payable, Maturity at June 3, 2016 [Member]
Short-term Debt [Line Items]	'	'	'	'	'	'	'
Convertible Debentures Payable, interest rate	'	10.00%	10.00%	10.00%	10.00%	10.00%	10.00%
Convertible Debentures Payable, maturity date	31-Jul-14	27-Feb-16	27-Feb-16	31-May-16	31-May-16	3-Jun-16	3-Jun-16

Stock_Based_Compensation_Detai

Stock Based Compensation (Details Narrative) (USD $)	9 Months Ended
	Jul. 31, 2014	Jul. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'
Stock-based employee compensation related to stock options	$0	$0

Stock_Based_Compensation_Sched

Stock Based Compensation - Schedule of Share-based Compensation, Stock Options Activity (Details) (USD $)	9 Months Ended	12 Months Ended
	Jul. 31, 2014	Oct. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'
Options, Outstanding, Beginning balance	30,000	30,000
Options, Granted	'	'
Options, Forfeited/Expired	'	'
Options, Exercised	'	'
Options, Outstanding, Ending balance	30,000	30,000
Weighted Average Exercise price, Outstanding, Beginning balance	$0.90	$0.90
Weighted Average Exercise price, Granted	'	'
Weighted Average Exercise price, Forfeited/Expired	'	'
Weighted Average Exercise price, Exercised	'	'
Weighted Average Exercise price, Outstanding, Ending balance	$0.90	$0.90

Warrants_Schedule_of_Warrants_

Warrants - Schedule of Warrants Outstanding (Details)	Jul. 31, 2014	Oct. 31, 2013
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	8,457,500	8,332,500
Issued To Flow Capital Advisors Inc On Settlement Of Lawsuit In August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.30 Per Common Share Up To And Including August 23, 2016 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	250,000	250,000
Issued To Flow Capital Advisors Inc On Settlement Of Lawsuit In August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.50 Per Common Share Up To And Including August 23, 2016 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	250,000	250,000
Issued To Flow Capital Advisors Inc On Settlement Of Lawsuit In August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.75 Per Common Share Up To And Including August 23, 2016 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	500,000	500,000
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $1.00 Per Common Share Up To And Including August 23, 2016. [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	500,000	500,000
Issued To Flow Capital Advisors Inc On Settlement Of Lawsuit In August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.75 Per Common Share Up To And Including August 23, 2016 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	500,000	500,000
Issued To Debenture Holders February 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.25 Per Common Share Up To And Including February 27, 2016 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	600,000	600,000
Issued To Debenture Holders May 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including June 3, 2016 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	750,000	750,000
Issued To Debenture Holders June 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including June 3, 2016	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	232,500	232,500
Issued to consultants in August 5, 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including August 4, 2023	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	2,500,000	2,500,000
Issued to consultants in August 5, 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.10 per common share up to and including August 4, 2023	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	1,500,000	1,500,000
Issued To Consultants In September 3, 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.50 Per Common Share Up To And Including July 31, 2018 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	500,000	500,000
Issued To Shareholder October 29, 2013 Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price of $0.15 Per Common Share Up To And Including October 29, 2016 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	250,000	250,000
Issued To Shareholder November 7, 2013 Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price of $0.15 Per Common Share Up To And Including November 7, 2016 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	125,000	'

Warrants_Schedule_of_Warrants_1

Warrants - Schedule of Warrants Outstanding (Details) (Parenthetical) (USD $)	9 Months Ended	12 Months Ended
	Jul. 31, 2014	Oct. 31, 2013
Issued To Flow Capital Advisors Inc On Settlement Of Lawsuit In August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.30 Per Common Share Up To And Including August 23, 2016 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$0.30	$0.30
Warrant, last exercisable date	23-Aug-16	23-Aug-16
Issued To Flow Capital Advisors Inc On Settlement Of Lawsuit In August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.50 Per Common Share Up To And Including August 23, 2016 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$0.50	$0.50
Warrant, last exercisable date	23-Aug-16	23-Aug-16
Issued To Flow Capital Advisors Inc On Settlement Of Lawsuit In August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.75 Per Common Share Up To And Including August 23, 2016 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$0.75	$0.75
Warrant, last exercisable date	23-Aug-16	23-Aug-16
Issued To Flow Capital Advisors Inc. On Settlement Of Lawsuit August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $1.00 Per Common Share Up To And Including August 23, 2016. [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$1	$1
Warrant, last exercisable date	23-Aug-16	23-Aug-16
Issued To Flow Capital Advisors Inc On Settlement Of Lawsuit In August 2011, Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price Of $0.75 Per Common Share Up To And Including August 23, 2016 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$0.75	$0.75
Warrant, last exercisable date	23-Aug-16	23-Aug-16
Issued To Debenture Holders February 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.25 Per Common Share Up To And Including February 27, 2016 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$0.25	$0.25
Warrant, last exercisable date	27-Feb-16	27-Feb-16
Issued To Debenture Holders May 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including June 3, 2016 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$0.15	$0.15
Warrant, last exercisable date	3-Jun-16	3-Jun-16
Issued To Debenture Holders June 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.15 Per Common Share Up To And Including June 3, 2016	'	'
Class of Warrant or Right [Line Items]	'	'
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$0.15	$0.15
Warrant, last exercisable date	3-Jun-16	3-Jun-16
Issued to consultants in August 5, 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.15 per common share up to and including August 4, 2023	'	'
Class of Warrant or Right [Line Items]	'	'
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$0.15	$0.15
Warrant, last exercisable date	4-Aug-23	4-Aug-23
Issued to consultants in August 5, 2013 entitling the holders to purchase 1 common share in the Company at an exercise price of $0.10 per common share up to and including August 4, 2023	'	'
Class of Warrant or Right [Line Items]	'	'
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$0.10	$0.10
Warrant, last exercisable date	4-Aug-23	4-Aug-23
Issued To Consultants In September 3, 2013 Entitling The Holders To Purchase 1 Common Share In The Company At An Exercise Price Of $0.50 Per Common Share Up To And Including July 31, 2018 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$0.50	$0.50
Warrant, last exercisable date	31-Jul-18	7-Nov-16
Issued To Shareholder October 29, 2013 Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price of $0.15 Per Common Share Up To And Including October 29, 2016 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$0.15	$0.15
Warrant, last exercisable date	29-Oct-16	29-Oct-16
Issued To Shareholder November 7, 2013 Entitling The Holder To Purchase 1 Common Share In The Company At An Exercise Price of $0.15 Per Common Share Up To And Including November 7, 2016 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrant, exchange ratio to common stock	1	1
Warrants, exercise price	$0.15	$0.15
Warrant, last exercisable date	7-Nov-16	7-Nov-16

Issuance_of_Common_Stock_Sched

Issuance of Common Stock - Schedule of Common Stock Issue (Details)	0 Months Ended	9 Months Ended
	Jan. 03, 2014	Jul. 31, 2014
		Common Stock [Member]
Issued for services rendered	'	116,279
Issued to shareholder for cash at $0.25 per share	'	200,000
Issued on conversion of notes payable	'	822,991
Issued on settlement of suit	700,000	700,000
Issued to minority shareholders on conversion of subsidiary's shares	'	296,538
Number of shares issued during period	'	2,135,808

Issuance_of_Common_Stock_Sched1

Issuance of Common Stock - Schedule of Common Stock Issue (Details) (Parenthetical) (USD $)	9 Months Ended
	Jul. 31, 2014
Stockholders' Equity Note [Abstract]	'
Equity price per share	$0.25

Net_Loss_per_Share_Details_Nar

Net Loss per Share (Details Narrative)	3 Months Ended		9 Months Ended
	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014	Jul. 31, 2013
Earnings Per Share [Abstract]	'	'	'	'
Incremental shares excluded from computation of diluted earning per share	15,367,845	8,532,918	15,367,845	8,532,918

Net_Loss_per_Share_Computation

Net Loss per Share - Computation of Weighted Average Shares Outstanding for Calculating Basic and Diluted Earnings Per Share (Details)	3 Months Ended		9 Months Ended
	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2014	Jul. 31, 2013
Earnings Per Share [Abstract]	'	'	'	'
Weighted-average shares - basic	60,938,316	56,676,166	60,260,456	56,676,166
Effect of dilutive securities	'	'	'	'
Weighted-average shares - diluted	60,938,316	56,676,166	60,260,456	56,676,166

Supplemental_Disclosure_of_Cas2

Supplemental Disclosure of Cash Flow Information - Cash Flow Supplemental Disclosures (Details) (USD $)	9 Months Ended
	Jul. 31, 2014	Jul. 31, 2013
Supplemental Cash Flow Elements [Abstract]	'	'
Cash paid during the period for, Interest	$12,352	$26,085
Cash paid during the period for, Income taxes	'	'
Conversion of notes payable	73,501	'
Settlement of derivative liability	98,276	'
Issuance of shares on settlement of suit	$189,000	'

Commitments_and_Contingent_Lia1

Commitments and Contingent Liabilities (Details Narrative) (USD $)	0 Months Ended	1 Months Ended
	Jan. 03, 2014	Apr. 22, 2009
Commitments and Contingencies Disclosure [Abstract]	'	'
Former employee related claims	'	$514,000
Litigation amount	$10,000	'
Payment of litigation amount by shares	700,000	'

Subsequent_Events_Details_Narr

Subsequent Events (Details Narrative) (USD $)	0 Months Ended				0 Months Ended	1 Months Ended
	Jun. 02, 2014	Jul. 31, 2014	15-May-14	Oct. 31, 2013	Sep. 17, 2014	Aug. 31, 2014	Sep. 30, 2014
					Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]
Notes payable	'	($41,206)	'	($11,983)	'	$15,000	'
Conversion of notes payable into common stock	5,507,979	'	'	'	5,007,253	250,000	'
Advanced by officer	'	'	'	'	'	'	9,183
Original debt amount	'	'	500,000	'	500,000	'	'
Interest payable	'	'	'	'	$50,798	'	'